Enzolytics Inc
OTC:ENZC
Net Margin
Enzolytics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Enzolytics Inc
OTC:ENZC
|
2.4m USD | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.9B USD |
7%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.6B USD |
17%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
138.8B USD |
21%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.4B USD |
-9%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.7B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.3B USD |
32%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43B USD |
-11%
|
Enzolytics Inc
Glance View
Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Plano, Texas. The company went IPO on 2008-12-29. The firm is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The firm is focused in developing monoclonal antibody therapy and treating infectious diseases. The company has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The firm has clinically tested anti-HIV therapeutics. The firm has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The firm has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The firm is testing these antibodies to prepare them for use as therapies against these diseases.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Enzolytics Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet